Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

Write your comment first

News feed

Khimprom reports for 2024 under IFRS

4/28/25 HIMCP

Sakhalinenergo reported under RAS for 3 months of 2025

4/28/25 SLEN

Segezha Group reported for 2024 according to RAS

4/28/25 SGZH

Artgen reported for 2024 by IFRS

4/28/25 ABIO

VTB resumes dividend payments

4/28/25 VTBR

INARCTICA reported for 3 months of 2025 by RAS

4/28/25 AQUA

Seligdar reports for 3 months of 2025 by RAS

4/28/25 SELG

Rosseti Siberia reported for 3 months of 2025 by RAS

4/28/25 MRKS

Magadanenergo reported for 3 months of 2025 according to RAS

4/28/25 MAGE

Delimobile has entered Yaroslavl

4/28/25 DELI